Cel-Sci closed at $1.37 on Nov 5, down 0.72%, 82.1% below its 52-week closing high. Volume of 99.2K shares was 0.65× its 20-day average (below normal).
Split-adjusted performance: -35.7% over one month, -14.4% over six months, -80.6% over one year.
Short interest was 663.8K shares at the Oct 15 settlement, up 12.1% from the prior report (4.0% of float, 1.6 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CVMCel-Sci | $1.37 | −0.72% | −14.4% | — | — | — | $24.1M | |
| MGXMetagenomi Therapeutics | $0.7308 | −7.49% | −48.5% | −103.0% | — | — | $27.6M | Compare |
| ALGSAligos Therapeutics | $4.51 | −10.16% | −25.2% | +2778.5% | −5.4% | — | $28.2M | Compare |
| BSEMBioStem Technologies | $1.04 | −9.57% | — | — | — | — | $19.4M | Compare |
| BKHABlack Hawk Acquisition | $4.50 | −19.21% | — | — | — | — | $18.7M | Compare |
| ESLAEstrella Immunopharma | $0.4101 | −7.53% | −67.7% | — | — | — | $17.8M | Compare |
| ELUTElutia | $0.7509 | −1.15% | −24.8% | −11.6% | −315.0% | 0.6 | $33.3M | Compare |
| PLURPluri | $1.19 | −3.26% | −64.4% | −15.8% | −1755.2% | — | $16.1M | Compare |
| INMBINmune Bio | $1.18 | −11.65% | −17.8% | — | — | — | $36.4M | Compare |
No recent articles focused on Cel-Sci.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
